Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VVT MedVVTMF Debt-to-Equity is -0.46 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 705 Medical Devices & Instruments companies, VVT Med ranks worse than 141843.83% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for VVT Med's Debt-to-Equity or its related term are showing as below:
VVTMF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.97 Med: -0.97 Max: -0.47
Current: -0.47
During the past 4 years, the highest Debt-to-Equity Ratio of VVT Med was -0.47. The lowest was -1.97. And the median was -0.97.
VVTMF's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.23
vs VVTMF: -0.47
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
VVT Med Debt-to-Equity Related Terms
VVT Med Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for VVT Med's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, VVT Med's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VVT Med Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VVT Med's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where VVT Med's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VVT Med (VVTMF) has a Debt-to-Equity of -0.46 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on VVT Med and its competitors. According to the industry distribution chart, VVT Med ranks #999999 out of 705 companies in the Medical Devices & Instruments industry.
Is VVT Med's Debt-to-Equity too high?
VVT Med's current Debt-to-Equity is -0.46. Based on the distribution chart, VVT Med ranks #999999 out of 705 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does VVT Med's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VVT Med ranks #999999 out of 705 companies for Debt-to-Equity. This places VVT Med in the lower half of its industry. The industry median Debt-to-Equity is 0.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on VVT Med and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VVT Med's current Debt-to-Equity is -0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VVT Med stock overvalued right now?
VVT Med (VVTMF) has a current Debt-to-Equity of -0.46. The current Debt-to-Equity is -0.46. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For VVT Med (VVTMF), the current Debt-to-Equity is -0.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VVT Med Inc is a medical device company, focused on developing and commercializing a range of minimally invasive technologies for treating varicose veins. VVT's research and development activities are based in Israel. The company proudly boasts three products within its portfolio that have achieved commercial production status and are currently available in the market. These products have undergone meticulous design processes, obtaining regulatory approvals across multiple countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVTMF has been successfully added to your 
